Express News | Apellis Pharmaceuticals Inc : Wedbush Cuts Target Price to $27 From $35
Syfovre's Competitive Edge Highlights Bright Future For Apellis Pharmaceuticals, Analyst Initiates With Bullish Pitch
Scotiabank Initiates Apellis Pharmaceuticals at Sector Perform With $35 Price Target
Express News | Apellis Pharmaceuticals Inc : William Blair Initiates Coverage With Outperform Rating; Fair Value Estimate $50
Express News | Apellis Announces Oral Presentation at American Society of Nephrology (Asn) Kidney Week on Phase 3 Valiant Study of Pegcetacoplan in C3G and Primary Ic-Mpgn
Apellis Announces Oral Presentation at American Society of Nephrology (ASN) Kidney Week on Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN
Wolfe's Tax Loss Selling Stocks Within Communications, Discretionary, Staples, Energy, Financials, Health Care
Wells Fargo Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating, Maintains Target Price $43
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Express News | Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Does Apellis Pharmaceuticals (NASDAQ:APLS) Have A Healthy Balance Sheet?
Mizuho Securities Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating, Maintains Target Price $39
Piper Sandler Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating, Cuts Target Price to $40
Piper Sandler Remains a Hold on Apellis Pharmaceuticals (APLS)
Apellis Pharmaceuticals to Host a Fireside Chat at the UBS Virtual Ophthalmology Day
Wells Fargo Maintains Equal-Weight on Apellis Pharmaceuticals, Lowers Price Target to $43
Wells Fargo Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating, Cuts Target Price to $43
Wells Fargo analyst Derek Archila maintains $Apellis Pharmaceuticals(APLS.US)$ with a hold rating, and adjusts the target price from $47 to $43.According to TipRanks data, the analyst has a success
Evaluating Market Dynamics and Physician Preferences: Hold Rating on Apellis Pharmaceuticals Amid Syfovre and Izervay Competition
Baird Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Cuts Target Price to $92
Baird analyst Colleen M. Kusy maintains $Apellis Pharmaceuticals(APLS.US)$ with a buy rating, and adjusts the target price from $96 to $92.According to TipRanks data, the analyst has a success rate
Express News | Apellis Pharmaceuticals Inc : Baird Cuts Target Price to $92 From $96